Metabolic synthetic lethality in cancer therapy
نویسندگان
چکیده
منابع مشابه
Cancer metabolism as a therapeutic target: metabolic synthetic lethality.
Interest in targeting metabolism as a possible cancer therapy has been renewed in recent years as research increases our understanding of the altered metabolic profile of cancer cells compared with that of normal cells. As mentioned by Drs. Batra, Rosen, and Shanmugam, metabolic reprogramming allows tumor cells to survive and proliferate in the hostile tumor environment. Alterations in tumor ce...
متن کاملProtease Addiction and Synthetic Lethality in Cancer
The "oncogene addiction" concept refers to the dependence of cancer cells on the function of the oncogenes responsible for their transformed phenotype, while the term "non-oncogene addiction" has been introduced to define the exacerbated necessity of the normal function of non-mutated genes. In this Perspective, we focus on the importance of proteolytic enzymes to maintain the viability of canc...
متن کاملLethality and synthetic lethality in the genome-wide metabolic network of Escherichia coli.
Recent genomic analyses on the cellular metabolic network show that reaction flux across enzymes are diverse and exhibit power-law behavior in its distribution. While intuition might suggest that the reactions with larger fluxes are more likely to be lethal under the blockade of its catalysing gene products or gene knockouts, we find, by in silico flux analysis, that the lethality rarely has co...
متن کاملSynthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.
UNLABELLED Metastatic solid tumors are almost invariably fatal. Patients with disseminated small-cell cancers have a particularly unfavorable prognosis, with most succumbing to their disease within two years. Here, we report on the genetic and functional analysis of an outlier curative response of a patient with metastatic small-cell cancer to combined checkpoint kinase 1 (CHK1) inhibition and ...
متن کاملSynthetic lethality--a new direction in cancer-drug development.
In this issue of the Journal, Fong et al. report the results of a phase 1 trial of a new cancer therapy involving 60 patients (ClinicalTrials.gov number, NCT00516373).1 Readers may be surprised by the editors’ decision to publish a small early-stage trial, but this trial not only reports important results — it also points to a new direction in the development of anticancer drugs. Modern cancerd...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biochimica et Biophysica Acta (BBA) - Bioenergetics
سال: 2017
ISSN: 0005-2728
DOI: 10.1016/j.bbabio.2016.12.003